Actualités 17.04.2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
News 17.04.2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
News 14.02.2024 University of Fribourg discovers drug to combat age-related neuroinflammation Scientists at the University of Fribourg have uncovered a groundbreaking mechanism that could significantly mitigate age-related neuroinflammatio...
News 10.01.2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
News 24.05.2023 Latest research shows 20% of European biotechs now headquartered in Switzerland Press release New research conducted by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20% of European biotech companies are now head...
Success stories 09.06.2022 La Svizzera offre condizioni interessanti e stabili per le aziende internazionali Merck Il leader scientifico e tecnologico Merck è presente in Svizzera da quasi un secolo. Oggi ha otto sedi, tra cui cinque impianti di produzione, e ...
Actualités 08.03.2021 Debiopharm signe un contrat de plus de EUR 900 millions avec Merck Debiopharm a accordé une licence mondiale exclusive au géant pharmaceutique Merck pour le développement et la commercialisation de son médicament...
News 08.03.2021 Debiopharm enters EUR 900+ million contract with Merck Debiopharm has granted a worldwide exclusive license to pharma giant Merck for the development and commercialization of its Xevinapant head and n...
News 05.07.2022 CHF 178 million to further develop life sciences in the canton of Vaud To consolidate the development of life sciences in the canton of Vaud, the State Council has announced an investment of CHF 178.71 million in the...
News 31.05.2022 RetinAI enters a multi-year software license agreement with Novartis Building on their existing relationship, Bern-based RetinAI and pharma giant Novartis have entered a long-term collaboration with a multi-year so...
News 12.01.2022 ObsEva achieves positive results in the treatment of endometriosis Geneva-based women’s health biopharmaceutical company ObsEva has announced positive topline results from the Phase 3 EDELWEISS 3 trial of linzago...
News 13.07.2021 Merck reaches key milestone in the construction of its Biotech Development Center Merck has celebrated the completion of the structural work on its Biotech Development Center currently under construction in Corsier-sur-Vevey.
Success stories 25.05.2023 Merck : “Switzerland offers attractive and stable conditions for international companies.“ Merck Science and technology leader Merck has been in Switzerland for almost a century. Today it has eight sites, including five manufacturing faciliti...
Success stories 25.05.2023 CSL Behring: “The deciding factors were time to market and the proven track record of the Bern site.” CSL Behring For over a century, CSL Behring (CSLB) has kept its founding promise to help patients suffering from rare and serious diseases. It specializes in...